The body in charge of pricing and reimbursement in Germany has downgraded the extent of additional benefit offered by Gilead’s Veklury for treating COVID-19 patients.
Gilead Sciences, Inc.’s Veklury (remdesivir) offers a minor added benefit over comparator therapies for one group of COVID-19 patients, the G-BA, the body in charge of pricing and reimbursement in Germany, has found.
Veklury first became available in Germany in May 2020, before it received conditional marketing approval from the European Commission the following July. Initially under development as a treatment for Ebola,...
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
